The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | Implementing liquid biopsies: advancing lung cancer care in the UK
Samreen Ahmed, University Hospitals of Leicester, UK, emphasizes the need for the UK to lead research efforts in implementing innovative approaches like liquid biopsies and circulating tumor DNA (ctDNA) testing for lung cancer treatment. While the UK boasts pioneering scientists in this field, there’s a gap in translating research findings into clinical practice nationwide. Prof. Ahmed discusses the importance of expanding access to ctDNA testing across various healthcare centers to address inequalities in cancer care and ensure all patients benefit from cutting-edge diagnostics and treatments. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
